HOME >> MEDICINE >> NEWS
Tamoxifen reduces risk of breast cancer, follow-up study confirms

Data from additional years of follow-up of a large randomized placebo-controlled clinical trial of tamoxifen for the prevention of breast cancer confirm that the drug reduces the risk of invasive and noninvasive breast cancer, according to a report that appears in the November 16 issue of the Journal of the National Cancer Institute.

The National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (P-1) began in 1992. More than 13,000 women aged 35 years and older who were at high risk for breast cancer were randomly assigned to receive either a placebo or tamoxifen for 5 years. In 1998, the study's independent data monitoring committee recommended that the study be unblinded. An overall 49% reduction in breast cancer risk was observed in women taking tamoxifen. Participants were informed of whether they were taking a placebo or tamoxifen so that women who were taking placebo could be given the option to take tamoxifen.

The initial findings from the study--which appeared in the Sept. 16, 1998, issue of the Journal of the National Cancer Institute--indicated that tamoxifen reduced the risk of invasive and noninvasive breast cancer. Tamoxifen was also found to reduce the risk of osteoporotic fractures but to increase the risks of endometrial cancer and thromboembolism.

In their follow up study, Bernard Fisher, M.D., and colleagues have updated the P 1 data. They found that, after 7 years of follow-up, the cumulative rate of invasive breast cancer was reduced by 43%, from 42.5 cases per 1,000 women in the placebo group to 24.8 cases per 1,000 women in the tamoxifen group. The rate of noninvasive breast cancer was reduced by 37%, from 15.8 cases per 1,000 women in the placebo group to 10.2 cases per 1,000 women in the tamoxifen group. The risks of stroke, deep-vein thrombosis, cataracts, ischemic heart disease, and death were similar to what was reported in 1998. The risk of pulmonary embolism was abou
'"/>

Contact: Kate Travis
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
15-Nov-2005


Page: 1 2

Related medicine news :

1. Tamoxifen discontinuation rates surprisingly high in clinical practice
2. Tamoxifen for breast cancer prevention does not benefit most women
3. Tamoxifen shows no benefit, risk for breast cancer survivors heart health
4. Tamoxifen can reduce breast pain in prostate cancer patients
5. Nonhormonal drug reduces hot flashes in men treated for prostate cancer
6. Circumcision reduces HIV infection risk
7. Retinol lotion reduces the fine wrinkles from natural aging of skin
8. Improving communication with families of dying patients reduces stress, anxiety and depression
9. New study: Pycnogenol reduces heart failure
10. Drinking farm milk reduces childhood asthma and allergies but raw consumption remains unsafe
11. Angioplasty reduces long-term cardiac risk among heart patients with silent ischemia

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/14/2018)... Ark. (PRWEB) , ... November 14, 2018 , ... ... Springs, Searcy, Cabot, Jacksonville, Austin, Ward and Romance, is celebrating its official grand opening ... 2018. Local families are encouraged to like and follow the Acti-Kare Facebook ...
(Date:11/14/2018)... ... November 14, 2018 , ... PAINWeekEnd on Saturday, December ... be an educational and exciting program providing busy clinicians and allied healthcare practitioners with ... According to the National Institute on Drug Abuse, Maryland is among the top five ...
(Date:11/14/2018)... Ill. (PRWEB) , ... November 14, 2018 , ... ... Period (OEP) is now underway began Nov. 1, 2018 and continues through Dec. ... prepared and gather necessary information, it does not have to be an overwhelming ...
(Date:11/13/2018)... ... November 14, 2018 , ... REMS: Requirements, Regulation, ... 28, 2018 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/remsrre ... a powerful enforcement tool. A constantly evolving enforcement tool. , In September the ...
(Date:11/13/2018)... , ... November 13, 2018 , ... ... device industries, announced today the opening of its newest laboratory located in Cary, ... aims to provide comprehensive services to top U.S. manufacturers and brings additional jobs ...
Breaking Medicine News(10 mins):
(Date:11/15/2018)... ... November 15, 2018 , ... ... Program (OTP) with locations in Salt Lake City and Ogden, Utah earlier ... a high-quality, trusted provider of evidence-based treatment for opioid addiction. The Metamorphosis ...
(Date:11/15/2018)... ... November 15, 2018 , ... In this month’s NEPC ... Gregory A. Smith and Cornell University professor Noliwe Rooks discuss ... , who also chairs the American Studies Program at Cornell, explore issues that have ...
(Date:11/15/2018)... (PRWEB) , ... November 15, 2018 , ... ... cloud computing arm of Alibaba Group, signed a Memorandum of Understanding (MoU) today ... areas of smart cities and smart healthcare. The two parties hope to translate ...
Breaking Medicine Technology:
Cached News: